


February 15, 2022

Siemens Healthineers AG

Annual Shareholders' Meeting



Virtual Annual Shareholders' Meeting of Siemens Healthineers AG for fiscal year 2021

Summary of the speech delivered by Dr. Bernd Montag, Chief Executive Officer

The spoken word shall prevail.

- As one of the world's most important companies in the healthcare industry, we once again stepped up to take responsibility in the second year of the global pandemic. The Siemens Healthineers team has supported medical personnel all over the world and along the entire clinical pathway of Covid-19, while at the same time helping to maintain the routine standard care provided by medical professionals.
- The financial figures of the year under review:
 - Revenue reached an all-time record level of 18 billion euros.
 - The adjusted EBIT margin was 17.4 percent.
 - Free cashflow jumped by 65 percent to 2.3 billion euros.
- Based on these outstanding business figures, we propose increasing the dividend per share from 80 to 85 euro cents. This corresponds to a payout ratio of 55 percent of net income.
- Through our combination with Varian, we have created a new company capable of shaping the future of healthcare all around the world. We now stand together in the fight against the most important diseases in neurology, cardiology, and oncology.
- Our customers appreciate that we share their passion and the enormous responsibility they bear: to work daily to make healthcare a little bit better, more affordable, and more humane – and available to more patients. Their trust in our comprehensive expertise and innovative strength provides the foundation for many longstanding partnerships. In the reporting period, we concluded 18 more agreements that we call "Value Partnerships"; in total, we're collaborating along these lines with 125 healthcare service providers in 28 different countries. We are therefore making a tangible contribution to the healthcare of entire societies.

- Health and sustainability go hand in hand. Just over a year ago we introduced our Sustainability Program with some very ambitious goals and measures. By 2025, we plan to increase by more than one quarter the frequency with which patients in underserved countries come into contact with our solutions. We've also committed to achieving climate neutrality by 2030.
- We want to be a company where all employees can make the best use of their skills, have the best opportunities for development and advancement, and feel most appreciated. To ensure we remain among the best in future, we're investing in the next generation's know-how. As of now, some 2,700 young people worldwide are preparing for their professional future in our company as trainees, students, or interns.
- Besides our investments in the best minds, we're also investing in the best infrastructure. Our ongoing expansion and new construction projects to erect state-of-the-art production, development and training locations around the globe made good progress over the past fiscal year and will continue to advance.
 - In Forchheim, Germany, we're investing 350 million euros to build our High Energy Photonics Center.
 - In Erlangen, Germany, we're investing 58 million euros to expand our existing vocational and advanced training center.
 - In Bengaluru, India, we're investing 160 million euros to build our new Innovation Hub there.
 - At our Innovation Hub in Shanghai, China, we're already collaborating with 20 local startup companies in the fields of imaging, artificial intelligence, and robotics.
- After an 18-year development period, our new computer tomograph NAEOTOM Alpha is carrying us into a whole new age of medical imaging. This provides physicians with superb images of microscopically small structures, showing for example calcification in coronary arteries. Patients benefit from exceedingly precise examinations and are exposed to substantially smaller doses of radiation and contrast agents. The response from customers has been extraordinarily positive. As with other pioneering innovations in the past, we'll once again be setting the pace.
- Last November, we elaborated on our next strategic phase, called "New Ambition", at our first Capital Market Day since becoming a listed company. We intend to achieve comparable annual growth of between six and eight percent. From 2022 to 2025, adjusted earnings per share are set to increase annually by between 12 and 15 percent. Thanks to our three unique competencies Patient Twinning, Precision Therapy, and Digital, Data and Artificial Intelligence, we can support our customers' efforts to overcome cost pressures and bridge shortages in medical staff – and ultimately help make healthcare systems smarter and more efficient.
- On behalf of the Managing Board, I wish to wholeheartedly thank all employees for what they've accomplished. To give this gratitude greater weight, this month we will be paying a one-off special bonus amounting in total to 56 million euros.
- Special thanks go to my colleague Christoph Zindel, who today is following our Annual Shareholders' Meeting one last time as a member of the Managing Board and will be stepping down from his position effective March 31, 2022. At the same time, I'm

delighted that Elisabeth Staudinger-Leibrecht was appointed as new Managing Board member as of December 1, 2021.

- It's a privilege for me every day to be part of this extraordinary team. The task of continuing our success story together with 66,000 colleagues worldwide represents a huge but wonderful responsibility.
- The Siemens Healthineers Historical Institute has just published a book on the history of our company. The book is available in bookstores.
- Together with my colleagues, I would like to thank our shareholders for their trust in our abilities and performance. Together, we pioneer breakthroughs in healthcare. For everyone. Everywhere.